论文部分内容阅读
目的 :本文对 1 996 - 0 1～ 1 998- 0 6收治的有骨痛症状的肺癌骨转移病人作回顾性分析。方法 :本文共 71例 ,治疗分两大组 :综合治疗组 46例 ,分为 3个亚组 ;A组 (化疗 +帕米磷酸钠 ) ,B组 (放疗 +帕米磷酸钠 ) ,C组 (核素 +帕米磷酸钠 ) ;单一疗法组 2 5例 ,分为 2个亚组 :D组 (化疗 ) ,E组 (放疗 )。结果 :综合组镇痛治疗有效率 89 1 % ,单一组 6 4 0 % (P <0 0 5 )。结论 :采用抗癌和破骨细胞抑制剂帕米磷酸钠综合治疗肺癌骨转移引起的疼痛 ,疗效满意 ,不良反应无相加 ,可进一步改善患者的生存质量。
Objective: The purpose of this study was to retrospectively analyze the patients with bone metastases from lung cancer who have been treated with bone pain from 1996 to 2001 to 1998. Methods: A total of 71 cases were divided into two groups: 46 cases in the comprehensive treatment group, which were divided into 3 subgroups: group A (chemotherapy plus pamidronate), group B (radiation plus pamidronate), group C (Nuclide + sodium pamidronate). In the monotherapy group, 25 patients were divided into two subgroups: group D (chemotherapy) and group E (radiation). Results: The total effective rate of analgesic therapy was 89.1% in the comprehensive group and was 64.0% in the single group (P <0.05). Conclusion: The anti-cancer and osteoclast inhibitor sodium pamidronate is effective in treating pain caused by bone metastasis of lung cancer. The curative effect is satisfactory and no adverse reactions are added, which can further improve the quality of life of patients.